How cystic fibrosis modulator therapy could transform Pseudomonas aeruginosa epidemiology
Microbiology · 2026
DOI: 10.1099/mic.0.001790 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microbiology, 2026. Verfasst von James Gurney und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Biology, Georgia State University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Pseudomonas aeruginosa, Pseudomonas Infections, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Cystic Fibrosis Foundation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
The advent of cystic fibrosis transmembrane conductance regulator modulators has revolutionized cystic fibrosis (CF) care by restoring epithelial ion transport and improving airway physiology in people with CF. These therapies reduce infection burden, especially from Pseudomonas aeruginosa , through enhanced mucociliary clearance and immune responses. Yet, P. aeruginosa often persists, raising concerns about microbial adaptation. Emerging evidence suggests that modulator-altered airways impose novel selective pressures, favouring mutations in genes linked to biofilm formation, iron metabolism and immune evasion. This may drive the emergence of strains adapted to a ‘hybrid’ airway; neither fully CF-like nor fully healthy. Such adaptations could potentially increase transmissibility or virulence, with implications beyond the CF population. Understanding how pathogens evolve under modulator pressure is essential in this new treatment era. Continued surveillance of microbial dynamics will be key to anticipating shifts in infection risk and informing future clinical and public health strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biology, Georgia State University, Atlanta, Georgia, USA.
- Center for Microbial Dynamics & Infection, School of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia, USA.
Förderung
- NIAID NIH HHS
- Cystic Fibrosis Foundation
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Zitieren
APA
Gurney, J., Letizia, M., Azimi, S., & Diggle, S. P. (2026). How cystic fibrosis modulator therapy could transform Pseudomonas aeruginosa epidemiology. Microbiology. https://doi.org/10.1099/mic.0.001790
Vancouver
Gurney J, Letizia M, Azimi S, Diggle SP. How cystic fibrosis modulator therapy could transform Pseudomonas aeruginosa epidemiology. Microbiology. 2026. doi:10.1099/mic.0.001790
BibTeX
@article{Gurney2026,
author = {Gurney, James and Letizia, Morgana and Azimi, Sheyda and Diggle, Stephen P},
title = {How cystic fibrosis modulator therapy could transform Pseudomonas aeruginosa epidemiology},
journal = {Microbiology},
year = {2026},
doi = {10.1099/mic.0.001790}
}
EUVIMED